Varicella routine vaccination and the effects on varicella epidemiology – results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011

BMC Infectious Diseases

Johannes G Liese¹  Christine Hagemann¹  David Carr¹  Veit Grote²  Andrea Streng¹ 

[1] Department of Paediatrics, University of Würzburg, Josef-Schneider-Str. 2, D-97080, Würzburg Germany;Department of Immunology and Infectiology, Children’s Hospital, University of Munich, Lindwurmstr 4, D-80337, Munich, Germany

关键词: Incidence;    Paediatric;    Hospitalisation;    Vaccination;    Coverage;    Surveillance;    Varicella;   

Others  :  1147270
DOI  :  10.1186/1471-2334-13-303

 received in 2012-12-05, accepted in 2013-06-24,  发布年份 2013

【 摘 要 】

Background

In 2004, routine varicella vaccination was recommended in Germany for children 11-14 months of age with one dose, and since 2009, with a second dose at 15-23 months of age. The effects on varicella epidemiology were investigated.

Methods

Data on varicella vaccinations, cases and complications were collected from annual parent surveys (2006-2011), monthly paediatric practice surveillance (Oct 2006 - Sep 2011; five varicella seasons) and paediatric hospital databases (2005-2009) in the area of Munich (about 238,000 paediatric inhabitants); annual incidences of cases and hospitalisations were estimated.

Results

Varicella vaccination coverage (1^st dose) in children 18-36 months of age increased in two steps (38%, 51%, 53%, 53%, 66% and 68%); second-dose coverage reached 59% in the 2011 survey. A monthly mean of 82 (62%) practices participated; they applied a total of 50,059 first-dose and 40,541 second-dose varicella vaccinations, with preferential use of combined MMR-varicella vaccine after recommendation of two doses, and reported a total of 16,054 varicella cases <17 years of age. The mean number of cases decreased by 67% in two steps, from 6.6 (95%CI 6.1-7.0) per 1,000 patient contacts in season 2006/07 to 4.2 (95%CI 3.9-4.6) in 2007/08 and 4.0 (95%CI 3.6-4.3) in 2008/09, and further to 2.3 (95%CI 2.0-2.6) in 2009/10 and 2.2 (95%CI 1.9-2.5) in 2010/11. The decrease occurred in all paediatric age groups, indicating herd protection effects. Incidence of varicella was estimated as 78/1,000 children <17 years of age in 2006/07, and 19/1,000 in 2010/11. Vaccinated cases increased from 0.3 (95%0.2-0.3) per 1,000 patient contacts in 2006/07 to 0.4 (95%CI 0.3-0.5) until 2008/09 and decreased to 0.2 (95%CI 0.2-0.3) until 2010/11. The practices treated a total of 134 complicated cases, mainly with skin complications. The paediatric hospitals recorded a total of 178 varicella patients, including 40 (22.5%) with neurological complications and one (0.6%) fatality due to varicella pneumonia. Incidence of hospitalisations decreased from 7.6 per 100,000 children <17 years of age in 2005 to 4.3 in 2009, and from 21.0 to 4.7 in children <5 years of age.

Conclusions

Overall, the results show increasing acceptance and a strong impact of the varicella vaccination program, even with still suboptimal vaccination coverage.

【 授权许可】

   
2013 Streng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, Rentier B, Rümke H, Sadzot-Delvaux C, Senterre J, Weil-Olivier C, Wutzler P: Varicella vaccination in Europe – taking the practical approach. BMC Med 2009, 7:26. BioMed Central Full Text
• [2]Nguyen HQ, Jumaan AO, Seward JF: Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005, 352(5):450-458.
• [3]Liese JG, Grote V, Rosenfeld E, Fischer R, Belohradsky BH, von Kries R, and the ESPED Varicella Study Group: The burden of varicella complications before the introduction of routine varicella vaccination in Germany. Pediatr Infect Dis J 2008, 27:119-124.
• [4]Grote V, von Kries R, Springer W, Hammersen G, Kreth HW, Liese J: Varicella-related deaths in children and adolescents – Germany 2003-2004. Acta Paediatr 2008, 97(2):187-192.
• [5]Rack AL, Grote V, Streng A, Belohradsky BH, Heinen F, von Kries R, Liese JG: Neurologic varicella complications before routine immunization in Germany. Pediatr Neurol 2010, 42(1):40-48.
• [6]Sadzot-Delvaux C, Rentier B, Wutzler P, Asano Y, Suga S, Yoshikawa T, Plotkin SA: Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis 2008, 197(Suppl 2):S185-S190.
• [7]Quian J, Rüttimann R, Romero C, Dall’Orso P, Cerisola A, Breuer T, Greenberg M, Verstraeten T: Impact of universal varicella vaccination of one year-olds in Uruguay: 1997-2005. Arch Dis Child 2008, 93:845-850.
• [8]Flatt A, Breuer J: Varicella vaccines. Br Med Bull 2012, 103:115-127.
• [9]EUVAC.NET: A surveillance community network for vaccine preventable infectious diseases. Varicella vaccination overview in European countries. 2012. http://www.euvac.net/graphics/euvac/vaccination/var.html webcite (accessed 04 July 2013)
• [10]Calendrier vaccinal recommandé au Luxembourg: Calendrier vaccinal recommandé au Luxembourg. 2012. http://www.sante.public.lu/fr/rester-bonne-sante/120-vaccinations/calendrier-vaccinal/index.html webcite (accessed 04 July 2013)
• [11]Reuss AM, Feig M, Kappelmayer L, Siedler A, Eckmanns T, Poggensee G: Varicella vaccination coverage of children under two years of age in Germany. BMC Publ Health 2010, 10:502. BioMed Central Full Text
• [12]Alfonsi V, D’Ancona F, Giambi C, Nacca G, Rota MC: Regional Coordinators for Infectious Diseases and Vaccinations: Current immunization policies for pneumococcal, meningococcal C, varicella and rotavirus vaccinations in Italy. Health Policy 2011, 103(2-3):176-183.
• [13]Boletin Epidemiológico de la Comunidad de Madrid: Varicela en la Comunidad de Madrid, años 2001 a 2009. Madrid 2010, 16:7.
• [14]Guris D, Jumaan AO, Mascola L, Watson BM, Zhang JX, Chaves SS, Gargiullo P, Perella D, Civen R, Seward JF: Changing varicella epidemiology in active surveillance sites – United States, 1995-2005. J Infect Dis 2008, 197(Suppl 2):S71-S75.
• [15]Marin M, Zhang JX, Seward JF: Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics 2011, 128:214-220.
• [16]Chaves SS, Lopez AS, Watson TL, Civen R, Watson B, Mascola L, Seward JF: Varicella in infants after implementation of the US varicella vaccination program. Pediatrics 2011, 128:1071-1077.
• [17]Shah SS, Wood SM, Luan X, Ratner AJ: Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr Infect Dis J 2010, 29(3):199-204.
• [18]Seward JF, Marin M, Vázquez M: Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 2008, 197(Suppl 2):S82-S89.
• [19]Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch Institut/Stand: Juli 2004. Epidemiol Bull 2004, 30:235-250.
• [20]Siedler A, Arndt U: Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill 2010, 15(13):19530.
• [21]Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch Institut/Stand: Juli 2009. Epidemiol Bull 2009, 30:279-298.
• [22]Höhle M, Siedler A, Bader HM, Ludwig M, Heininger U, von Kries R: Assessment of varicella vaccine effectiveness in Germany: a time-series approach. Epidemiol Infect 2011, 139:1710-1719.
• [23]Robert Koch-Institut: Gemeinsamer Varizellen-Workshop von AGMV und BaVariPro. Epidemiol Bull 2010, 8:69-75.
• [24]Streng A, Seeger K, Grote V, Liese JG: Varicella vaccination coverage in Bavaria (Germany) after general vaccine recommendation in 2004. Vaccine 2010, 28:5738-5745.
• [25]Bayerisches Landesamt für Statistik und Datenverarbeitung: Altersstruktur der Bevölkerung Bayerns. 2012. https://www.statistik.bayern.de/veroeffentlichungen/index.php?themenbereich=3100 webcite (accessed 04 July 2013)
• [26]Rentier B, Gershon AA: Consensus: varicella vaccination of healthy children – a challenge for Europe. Pediatr Infect Dis J 2004, 23:379-389.
• [27]Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A: Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine. Pediatr Infect Dis J 2007, 26(7):632-638.
• [28]Bedford H, Lansley M: More vaccines for children? Parents’ views. Vaccine 2007, 25(45):7818-7823.
• [29]World Health Organization: Varicella vaccines. WHO position paper. Wkly Epidemiol Rec 1998, 73:241-248.
• [30]Spackova M, Muehlen M, Siedler A: Complications of varicella after implementation of routine childhood varicella vaccination in Germany. Pediatr Infect Dis J 2010, 29:884-886.
• [31]Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, Chan I, Study Group for Varivax: Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004, 23:132-137.
• [32]Marin M, Meissner HC, Seward JF: Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008, 122:e744-e751.
• [33]Pozza F, Piovesan C, Russo F, Bella A, Pezzotti P, Emberti Gialloreti E: Impact of universal vaccination on the epidemiology of varicella in Veneto, Italy. Vaccine 2011, 29:9480-9487.
• [34]Giammanco G, Ciriminna S, Barberi I, Titone L, Lo Giudice M, Biasio LR: Universal varicella vaccination in the Sicilian paediatric population: rapid uptake of the vaccination programme and morbidity trends over five years. Euro Surveill 2009, 14(35):19321.
• [35]Cenoz MG, Catalán JC, Zamarbide FI, Berastegui MA, Gurrea AB: [Impact of universal vaccination against chicken pox in Navarre, 2006-2010]. An Sist Sanit Navar 2011, 34:193-202.
• [36]Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, Tischer A, Andrews N, Berbers G, Gabutti G, Gay N, Jones L, Jokinen S, Kafatos G, de Aragón MV, Schneider F, Smetana Z, Vargova B, Vranckx R, Miller E: The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 2007, 25:7866-7872.
• [37]Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB: The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008. Epidemiol Infect 2012, 140:1131-1140.
• [38]Carville KS, Riddell MA, Kelly HA: A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine 2010, 28:2532-2538.
• [39]Khandaker G, Marshall H, Peadon E, Zurynski Y, Burgner D, Buttery J, Gold M, Nissen M, Elliott EJ, Burgess M, Booy R: Congenital and neonatal varicella: impact of the national varicella vaccination programme in Australia. Arch Dis Child 2011, 96:453-456.
• [40]Tan B, Bettinger J, McConnell A, Scheifele D, Halperin S, Vaudry W, Law B: Members of the Canadian Immunization Monitoring Program, Active (IMPACT): The effect of funded varicella immunization programs on varicella-related hospitalizations in IMPACT centers, Canada, 2000-2008. Pediatr Infect Dis J 2012, 31(9):956-963.
• [41]Ulloa-Gutierrez R, Miño G, Odio C, Avila-Aguero M, Brea J: Vaccine-preventable diseases and their impact on Latin American children. Expert Rev Vaccine 2011, 10:1671-1673.
• [42]Lopez AS, Kolasa MS, Seward JF: Status of school entry requirements for varicella vaccination and vaccination coverage 11 years after implementation of the varicella vaccination program. JID 2008, 197:S76-S81.
• [43]Marin M, Broder KR, Temte JL, Snider DE, Seward JF, Centers for Disease Control and prevention (CDC): Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59(rr-3):1-12.
• [44]Robert Koch-Institut: Zur Kombinationsimpfung gegen Masern, Mumps, Röteln und Varizellen (MMRV). Epidemiol Bull 2011, 38:352-353.
• [45]Robert Koch-Institut: Evaluation der Varizellen-Impfempfehlung durch die STIKO. Epidemiol Bull 2013, 1:1-5.
• [46]Robert Koch-Institut: Falldefinitionen zur Übermittlung von Erkrankungs- und Todesfällen sowie von Erregernachweisen von Mumps, Pertussis, Röteln und Varizellen. Bundesgesundheitsbl 2013. http://www.rki.de/DE/Content/Infekt/IfSG/Falldefinition/Falldefinition_MRPV.pdf?__blob=publicationFile webcite (accessed 04 July 2013). doi:10.1007/s00103-013-1696-3